Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.
Identifieur interne : 000841 ( PubMed/Checkpoint ); précédent : 000840; suivant : 000842Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.
Auteurs : R J Kastner [Suisse] ; C M Stone [Suisse] ; P. Steinmann [Suisse] ; M. Tanner [Suisse] ; F. Tediosi [Suisse]Source :
- Advances in parasitology [ 2163-6079 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Antihelminthiques.
- traitement médicamenteux : Filariose lymphatique.
- économie : Filariose lymphatique.
- Analyse coût-bénéfice, Animaux, Brugia, Filariose lymphatique, Humains, Modèles théoriques, Éradication de maladie.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Anthelmintics.
- drug effects : Brugia.
- drug therapy : Elephantiasis, Filarial.
- economics : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Animals, Cost-Benefit Analysis, Disease Eradication, Humans, Models, Theoretical.
Abstract
In the last few years, the concepts of disease elimination and eradication have again gained consideration from the global health community, with Guinea worm disease (dracunculiasis) on track to become the first parasitic disease to be eradicated. Given the many complex and interlinking issues involved in committing to a disease eradication initiative, such commitments must be based on a solid assessment of a broad range of factors. In this chapter, we discuss the value and implications of undertaking a systematic and fact-based analysis of the overall situation prior to embarking on an elimination or eradication programme. As an example, we draw upon insights gained from a series of lymphatic filariasis (LF) studies from our research group that adopted an eradication investment case (EIC) framework. The justification for EICs, and related epidemiological, geospatial and other mathematical/operational research modelling, stems from the necessity for proper planning prior to committing to disease eradication. Across all considerations for LF eradication, including: time, treatments, level of investments necessary, health impact, cost-effectiveness, and broader economic benefits, scaling-up mass drug administration coverage to all endemic communities immediately provided the most favourable results. The coherent and consistent pursuit of eradication goals, operationally tailored to a given socioecological system and based on integrated measures of available tools will lead relatively rapidly to elimination in many parts of endemic areas and provide the cornerstone towards eradication.
DOI: 10.1016/bs.apar.2016.08.004
PubMed: 27756458
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27756458Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.</title><author><name sortKey="Kastner, R J" sort="Kastner, R J" uniqKey="Kastner R" first="R J" last="Kastner">R J Kastner</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Stone, C M" sort="Stone, C M" uniqKey="Stone C" first="C M" last="Stone">C M Stone</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Steinmann, P" sort="Steinmann, P" uniqKey="Steinmann P" first="P" last="Steinmann">P. Steinmann</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Tanner, M" sort="Tanner, M" uniqKey="Tanner M" first="M" last="Tanner">M. Tanner</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Tediosi, F" sort="Tediosi, F" uniqKey="Tediosi F" first="F" last="Tediosi">F. Tediosi</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27756458</idno><idno type="pmid">27756458</idno><idno type="doi">10.1016/bs.apar.2016.08.004</idno><idno type="wicri:Area/PubMed/Corpus">000568</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000568</idno><idno type="wicri:Area/PubMed/Curation">000568</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000568</idno><idno type="wicri:Area/PubMed/Checkpoint">000568</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000568</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.</title><author><name sortKey="Kastner, R J" sort="Kastner, R J" uniqKey="Kastner R" first="R J" last="Kastner">R J Kastner</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Stone, C M" sort="Stone, C M" uniqKey="Stone C" first="C M" last="Stone">C M Stone</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Steinmann, P" sort="Steinmann, P" uniqKey="Steinmann P" first="P" last="Steinmann">P. Steinmann</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Tanner, M" sort="Tanner, M" uniqKey="Tanner M" first="M" last="Tanner">M. Tanner</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Tediosi, F" sort="Tediosi, F" uniqKey="Tediosi F" first="F" last="Tediosi">F. Tediosi</name><affiliation wicri:level="1"><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><series><title level="j">Advances in parasitology</title><idno type="eISSN">2163-6079</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anthelmintics (administration & dosage)</term><term>Brugia (drug effects)</term><term>Cost-Benefit Analysis</term><term>Disease Eradication</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (economics)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Humans</term><term>Models, Theoretical</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Antihelminthiques (administration et posologie)</term><term>Brugia ()</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (économie)</term><term>Humains</term><term>Modèles théoriques</term><term>Éradication de maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anthelmintics</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antihelminthiques</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brugia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cost-Benefit Analysis</term><term>Disease Eradication</term><term>Humans</term><term>Models, Theoretical</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Brugia</term><term>Filariose lymphatique</term><term>Humains</term><term>Modèles théoriques</term><term>Éradication de maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the last few years, the concepts of disease elimination and eradication have again gained consideration from the global health community, with Guinea worm disease (dracunculiasis) on track to become the first parasitic disease to be eradicated. Given the many complex and interlinking issues involved in committing to a disease eradication initiative, such commitments must be based on a solid assessment of a broad range of factors. In this chapter, we discuss the value and implications of undertaking a systematic and fact-based analysis of the overall situation prior to embarking on an elimination or eradication programme. As an example, we draw upon insights gained from a series of lymphatic filariasis (LF) studies from our research group that adopted an eradication investment case (EIC) framework. The justification for EICs, and related epidemiological, geospatial and other mathematical/operational research modelling, stems from the necessity for proper planning prior to committing to disease eradication. Across all considerations for LF eradication, including: time, treatments, level of investments necessary, health impact, cost-effectiveness, and broader economic benefits, scaling-up mass drug administration coverage to all endemic communities immediately provided the most favourable results. The coherent and consistent pursuit of eradication goals, operationally tailored to a given socioecological system and based on integrated measures of available tools will lead relatively rapidly to elimination in many parts of endemic areas and provide the cornerstone towards eradication.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27756458</PMID><DateCreated><Year>2016</Year><Month>10</Month><Day>19</Day></DateCreated><DateCompleted><Year>2017</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2163-6079</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Advances in parasitology</Title><ISOAbbreviation>Adv. Parasitol.</ISOAbbreviation></Journal><ArticleTitle>Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.</ArticleTitle><Pagination><MedlinePgn>393-417</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0065-308X(16)30080-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.apar.2016.08.004</ELocationID><Abstract><AbstractText>In the last few years, the concepts of disease elimination and eradication have again gained consideration from the global health community, with Guinea worm disease (dracunculiasis) on track to become the first parasitic disease to be eradicated. Given the many complex and interlinking issues involved in committing to a disease eradication initiative, such commitments must be based on a solid assessment of a broad range of factors. In this chapter, we discuss the value and implications of undertaking a systematic and fact-based analysis of the overall situation prior to embarking on an elimination or eradication programme. As an example, we draw upon insights gained from a series of lymphatic filariasis (LF) studies from our research group that adopted an eradication investment case (EIC) framework. The justification for EICs, and related epidemiological, geospatial and other mathematical/operational research modelling, stems from the necessity for proper planning prior to committing to disease eradication. Across all considerations for LF eradication, including: time, treatments, level of investments necessary, health impact, cost-effectiveness, and broader economic benefits, scaling-up mass drug administration coverage to all endemic communities immediately provided the most favourable results. The coherent and consistent pursuit of eradication goals, operationally tailored to a given socioecological system and based on integrated measures of available tools will lead relatively rapidly to elimination in many parts of endemic areas and provide the cornerstone towards eradication.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kastner</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinmann</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tediosi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Adv Parasitol</MedlineTA><NlmUniqueID>0370435</NlmUniqueID><ISSNLinking>0065-308X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002009" MajorTopicYN="N">Brugia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">EPIFIL</Keyword><Keyword MajorTopicYN="Y">Elimination and eradication of infectious diseases</Keyword><Keyword MajorTopicYN="Y">Eradication investment case</Keyword><Keyword MajorTopicYN="Y">Global Malaria Eradication Programme</Keyword><Keyword MajorTopicYN="Y">Global Programme to Eliminate Lymphatic Filariasis</Keyword><Keyword MajorTopicYN="Y">Incremental cost-effectiveness ratio</Keyword><Keyword MajorTopicYN="Y">Lymphatic filariasis</Keyword><Keyword MajorTopicYN="Y">Mass drug administration</Keyword><Keyword MajorTopicYN="Y">Mathematical modelling</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27756458</ArticleId><ArticleId IdType="pii">S0065-308X(16)30080-X</ArticleId><ArticleId IdType="doi">10.1016/bs.apar.2016.08.004</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Kastner, R J" sort="Kastner, R J" uniqKey="Kastner R" first="R J" last="Kastner">R J Kastner</name></noRegion><name sortKey="Steinmann, P" sort="Steinmann, P" uniqKey="Steinmann P" first="P" last="Steinmann">P. Steinmann</name><name sortKey="Stone, C M" sort="Stone, C M" uniqKey="Stone C" first="C M" last="Stone">C M Stone</name><name sortKey="Tanner, M" sort="Tanner, M" uniqKey="Tanner M" first="M" last="Tanner">M. Tanner</name><name sortKey="Tediosi, F" sort="Tediosi, F" uniqKey="Tediosi F" first="F" last="Tediosi">F. Tediosi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000841 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000841 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27756458
|texte= Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27756458" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |